Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Post-authorization Safety Study of Ustekinumab in the Treatment of Pediatric Patients Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis

NCT03218488 is registered in ClinicalTrials.gov with Janssen-Cilag International NV as lead sponsor.

NCT NCT03218488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03218488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Post-authorization Safety Study of Ustekinumab in the Treatment of Pediatric Patients Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
Lead sponsor
Janssen-Cilag International NV
Phase
Observational
Overall status
Active, not recruiting
Start date
October 25, 2017
Completion date
August 31, 2032
Enrollment
135 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis